Forte Biosciences, Inc. (FBRX)

0.7141 +0.0141 (+2.01%) At close: 04:00PM EDT

Forte Biosciences, Inc.

3060 Pegasus Park Drive
Building 6
Dallas, TX 75247
United States
310 618 6994
https://www.fortebiorx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 9

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Paul A. Wagner Ph.D.	CEO, President & Chairman	960.23k	N/A	1970
Mr. Antony A. Riley CPA	Chief Financial Officer	568.48k	N/A	1967
Dr. Barbara K. Finck M.D.	Chief Medical Clinician & Director	45k	N/A	1947
Mr. Christopher Roenfeldt	Chief Operating Officer	N/A	N/A	N/A
Mr. Steven Ruhl	Chief Technical Officer	N/A	N/A	1957

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Corporate governance

Forte Biosciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.